Senbanjo et al. demonstrated that CD44 regulates RUNX2 expression in prostate cancer, and that the interaction between RUNX2 and CD44 promotes the expression of metastasis-associated genes, such as osteopontin (OPN) and MMP-9, which in turn promotes the migration and invasion of prostate cancer cells [133]. Here, RUNX2 is linked to prostate cancer.